Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information. •≥ 18 years old at the time of informed consent * Patients with histologically confirmed diagnosis of cancer NOTE: Patients with active cancer or post treatment are allowed on the study. * Patients must be receiving stable or increasing doses of morphine for 1-2 weeks prior to registration for protocol therapy. NOTE: Switching patient from current pain regimen to morphine equivalent for at least 1-2 weeks prior to registration for protocol therapy is required. * Requiring greater than or equal to 180 mg of morphine per day. See Appendix 1 for Morphine Conversion Calculator. * Inadequately controlled pain even with the use of morphine (VAS score \>5) See Appendix 8 * Rescue pain medications are allowed this may include the use of NSAIDS or Tylenol as well as morphine IR. * ECOG Performance Status of 0-2 * Ability to swallow and tolerate oral tablets. * Patients getting radiation therapy are allowed at the discretion of the treating physician. * Females of childbearing potential must have a negative pregnancy test NOTE: Females are considered of child bearing potential unless they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal (\> 12 months since last menses). NOTE: Females using hormonal contraceptives should be switched to non-hormonal forms of contraception. The following laboratory values must be obtained. Patient with aplastic anemia will be excluded. * White blood cell count (WBC) ≥ 3.0 K/mm3 * Absolute neutrophil count ≥ 1.5 K/mm3 * Hemoglobin (Hgb) ≥ 9 g/dL * Platelets ≥ 75 K/mm3 * Creatinine ≤ 1.5 mg/dl * Bilirubin ≤ 1.5 x ULN * Aspartate aminotransferase (AST, SGOT) ≤ 3 x ULN * Alanine aminotransferase (ALT, SGPT) ≤ 3 x ULN Exclusion Criteria: • Active central nervous system (CNS) metastases. Patients with neurological symptoms should undergo a head CT scan or brain MRI to exclude brain metastasis, at the discretion of the treating physician. NOTE: Patients with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic. • Concurrent use of adjuvant medication such as but not limited to: gabapentin, pregabalin or duloxetine etc. NOTE: Patients on gabapentin or pregabalin can be considered if they can be tapered off before enrolling on the study. * Treatment with any investigational agent within 30 days prior to registration for protocol therapy. * Patient with rapidly escalating pain that require hospitalization or an intravenous opioid therapy * Concurrent participation in a clinical trial which involves another investigational agent. * Concurrent use of medications that are strong CYP3A4 inhibitors within 14 days prior to registration for protocol therapy as Oxcarbazepine is strong CYP3A4 inducer. See Appendix 7. NOTE: Concurrent use of other CYP3A4 inhibitors may be allowed at the discretion of the treating physician or principal investigator. * Allergic reaction to carbamazepine or oxcarbazepine (HLA-B1502) * Allergy or other contraindication to morphine sulphate * Opiate-induced uncontrolled constipation or bowel obstruction * Patient who lives alone. * Female who is pregnant or breastfeeding * Patient who has a diagnosis of epilepsy and/or is currently taking anti-epileptic drugs